

# Outcomes of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

*Kosuke Takemura<sup>a,\*</sup>, Jeffrey Graham<sup>b</sup>, David Maj<sup>c</sup>, Martin Zarba<sup>c</sup>, J. Connor Wells<sup>d</sup>, Razane El Hajj Chehade<sup>e</sup>, Marc Eid<sup>e</sup>, Eddy Saad<sup>e</sup>, Renee Maria Saliby<sup>e</sup>, Jae-Lyun Lee<sup>f</sup>, Frede Donskov<sup>g,h</sup>, Benoit Beuselinck<sup>i</sup>, Evon Jude<sup>j</sup>, Rana R. McKay<sup>k</sup>, Naveen S. Basappa<sup>l</sup>, Sumanta K. Pal<sup>m</sup>, Camillo Porta<sup>n</sup>, Neeraj Agarwal<sup>o</sup>, Toni K. Choueiri<sup>e</sup>, Daniel Y.C. Heng<sup>c</sup>*

<sup>a</sup> Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; <sup>b</sup> CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada; <sup>c</sup> Arthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB, Canada; <sup>d</sup> Barts Cancer Institute, Queen Mary University of London, London, UK; <sup>e</sup> Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; <sup>f</sup> Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; <sup>g</sup> Aarhus University Hospital, Aarhus, Denmark; <sup>h</sup> University Hospital of Southern Denmark, Esbjerg, Denmark; <sup>i</sup> Leuven Cancer Institute, KU Leuven, Leuven, Belgium; <sup>j</sup> Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, VIC, Australia; <sup>k</sup> Moores Cancer Center, University of California San Diego, La Jolla, CA, USA; <sup>l</sup> Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; <sup>m</sup> City of Hope Comprehensive Cancer Center, Duarte, CA, USA; <sup>n</sup> University of Bari Aldo Moro, Bari, Italy; <sup>o</sup> Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA